Global Internal and Collaboration Pipeline

Phase 1
- Sonrotoclax BCL2
  - B-cell malignancies
  - AML/MDS
  - MM t(11;14)

- BGB-16673 BTK CDAC
  - B-cell malignancies

- BGB-21447 next gen BCL2
  - B-cell malignancies

- BGB-A445 OX40
  - Solid tumors

- Surzebiclimab TIM3
  - Solid tumors

- BGB-15025 / 26808 HPK1
  - 15025- Solid tumors
  - 26808- Solid tumors

- BGB-30813 DGKζ
  - Solid tumors

- BGB-A3055 CCR8
  - Solid tumors

- BGB-24714 SMAC mimetic
  - Solid tumors

- BGB-10188 PI3Kδ
  - Solid tumors

- BGB-43395 CDK4
  - BC & Solid tumors

- Zanidatamab HER2 BsAb
  - 1L mBC/OC

- Xaluritamig STEAP1 x CD3
  - 20180146 mCRPC (initiation activities)

Phase 2
- Zanubrutinib BTK
  - B-cell lymphoma
  - CD79B R/R DLBCL
  - Lupus nephritis

- Sonrotoclax BCL2
  - R/R MCL
  - R/R CLL
  - R/R WM

- Ociperlimab TIGIT
  - 1L NSCLC
  - LBL-007³ LAG3

- BGB-A445 OX40
  - Melanoma, RCC, UC

- Umbrella Studies Multiple
  - 1L NSCLC
  - 2L+ NSCLC

- Zanidatamab HER2 BsAb
  - HER2+ 2L BTC

Phase 3
- Zanubrutinib BTK
  - TN MCL
  - R/R MZL, R/R FL
  - pMN

- Sonrotoclax BCL2
  - TN CLL

- Tislelizumab PD1
  - Neo-adj NSCLC
  - LA ESCC
  - R/R chHL

- Ociperlimab TIGIT
  - 1L NSCLC PD1-high

- Zanidatamab HER2 BsAb
  - 1L HER2+ GEA

- Tariqatamab2 DLL3 x CD3
  - 20210004 2L SCLC

Registration
- Zanubrutinib BTK
  - TN CLL/SL (US, EU, CN, Others)
  - R/R CLL/SL (US, EU, Others)
  - R/R FL (CN)
  - TN R/R WM (JP)

- Tislelizumab PD1
  - 1L NSCLC (EU)
  - 2/3L NSCLC (EU)
  - 1L Sq. NSCLC (CN)
  - 1L ES-SCLC (CN)
  - 1L GC/GEJC (TT-US, CN)
  - 1L ESCC (US, EU)
  - 2L ESCC (US)

- Pamiparib PARP
  - 2L MTx gBRCAm PSOC

- Ociperlimab TIGIT
  - 1L NSCLC PD1-high

- Zanidatamab HER2 BsAb
  - 1L HER2+ GEA

- Tariqatamab2 DLL3 x CD3
  - 20210004 2L SCLC

Approved
- Zanubrutinib BTK
  - TN CLL/SL (US, EU, CN, Others)
  - R/R CLL/SL (US, EU, Others)
  - R/R FL (CN)
  - TN R/R WM (US, EU, CN, Others)

- Tislelizumab PD1
  - 1L Non-sq. NSCLC (CN)
  - 1L Sq. NSCLC (CN)
  - 2/3L NSCLC (CN)
  - 1L GC (CN)
  - 1L HCC (CN)
  - 2/3L HCC (CN)
  - 1L EBSC (CN)
  - 2L EBSC (EU, CN)
  - 1L NPC (CN)
  - 2L MSI-H/dMMR (CN)
  - R/R chHL (CN)

- Pamiparib PARP
  - 2L gBRCAm OC (CN)

Registration includes select accepted submissions
1. Primary endpoint met; CN = China
2. Amgen collaboration, BeiGene will have China commercial rights and tiered mid-single digit royalties on net sales outside of China. "Initiation activities" refers to clinical activities, approval is obtained to initiate the study in China.
3. Leads Biolabs collaboration, BeiGene has ex-China commercial rights

Updated March 2024